Get started Log in

APLM — Apollomics Share News

0.000.00%

Last trade - 00:00

FinancialsSpeculativeMicro CapMomentum Trap

Market Cap
$38.43m
Enterprise Value
$35.79m
Revenue
$8.50m

Brief: Apollomics Announces Efficacy Of Vebreltinib In Nsclc Patients With Metex14 Skipping Mutation Achieving An Overall Response Rate (Orr) Of 75%
23/10/2023 14:23
Brief: Orbimed Advisors Llc Reports 20.2% Stake In Apollomics Inc As Of Sept 29 - SEC Filing
02/10/2023 21:54
Brief: Apollomics Reports First Half 2023 Financial Results, Provides Corporate Update
28/09/2023 23:23
Brief: Maxpro Capital Acquisition Corp Confirms Additional Funding, Extension Of Deadline To Complete Initial Business Combination
13/01/2023 22:01
Brief: Maxpro Capital Acquisition Corp Announces Deadline Extension For Business Combination
10/01/2023 21:13
Brief: Apollomics Inc. Receives FDA Orphan Drug Designation For Vebreltinib (Apl-101) For Treatment Of Non-Small Cell Lung Cancer With Met Genomic Tumor Aberrations
15/11/2022 13:15
Brief: Maxpro Capital Acquisition Corp Confirms Additional Funding And Extension Of Deadline To Complete Initial Business Combination
14/10/2022 22:38
Brief: Maxpro Capital Announces Extension To Deadline To Complete Business Combination
07/10/2022 22:19
Brief: Apollomics Inc To Be Listed On Nasdaq Through Business Combination With Maxpro Capital Acquisition Corp
14/09/2022 15:49